PRKAA1 and hepatocellular carcinoma: This was strikingly shown by Favre and collaborators that demonstrated how the antitumor effects of AMPK in hepatocellular carcinoma (HCC) cells can be greatly reduced by PKA-driven AMPKα1-Ser184 phosphorylation and the consequent diminution of AMPK activation 64.